US Pharm. 2013;38(3):7.
Phoenix, AZ—Taking regular doses of selumetinib has resulted in tumor stabilization or shrinkage in many women with low-grade serous carcinoma of the ovary or peritoneum, according to researchers. In what is considered a potentially important breakthrough, the compound targets a mutation in the mitogen-activated protein kinase pathway in patients with low-grade serous carcinoma, permitting treatment of previously chemoresistant tumors. Of 52 participants in the phase II trial, eight had a measurable decrease in tumor size, seven showed a partial response, and 34 experienced tumor stabilization. Phase III of this trial, which is scheduled to begin shortly, will be the definitive test before the treatment is made available to the general population.
To comment on this article, contact rdavidson@uspharmacist.com.
